Literature DB >> 33596468

Antimicrobial susceptibility testing of Eggerthella lenta blood culture isolates at a university hospital in Belgium from 2004 to 2018.

Baptist Declerck1, Yolien Van der Beken2, Deborah De Geyter3, Denis Piérard3, Ingrid Wybo3.   

Abstract

OBJECTIVES: Eggerthella lenta is a Gram-positive anaerobic bacillus that is an important cause of bloodstream infections. This study aims to test the susceptibility of Eggerthella lenta blood culture isolates to commonly used antibiotics for the empirical treatment of anaerobic infections.
METHODS: In total, 49 positive blood cultures for Eggerthella lenta were retrospectively included from patients hospitalised at the Universitair Ziekenhuis Brussel, Belgium, between 2004 and 2018. Identification was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) system. Antimicrobial susceptibility testing was performed using the reference agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines with Brucella agar supplemented with 5 μg/mL hemin, 1 μg/mL vitamin K1 and 5% laked sheep blood. The minimal inhibitory concentrations were interpreted using the EUCAST breakpoints. Clinical characteristics were collected by reviewing the patient's medical records.
RESULTS: All isolates were susceptible to amoxicillin-clavulanate, metronidazole and meropenem. Eighty-eight % of them were susceptible to clindamycin and 94% (20% S, 74% I) were susceptible to piperacillin-tazobactam. The mean age of the patients was 64 (±20) and they showed a 30-day mortality of 27%. The source of infection was in 65.3% of the cases abdominal, 20.4% were sacral pressure ulcers and 14.3% were unknown causes. While all isolates were fully susceptible at standard dosing regimen to amoxicillin-clavulanate, most were only susceptible at increased exposure or resistant to piperacillin-tazobactam.
CONCLUSIONS: Our results suggest to be careful with the use of piperacillin-tazobactam and clindamycin in the empirical treatment of Eggerthella lenta infections.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility testing; Blood culture; Eggerthella lenta

Year:  2021        PMID: 33596468     DOI: 10.1016/j.anaerobe.2021.102348

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  3 in total

1.  Sepsis caused by Eggerthelle lenta: a case report.

Authors:  Li-Chao Sun; Wan-Ling Xu; Jian-Nan Chai; Li Pang; Xiu-Xian Zang; Wei Li; Ji-Hong Xing
Journal:  World J Emerg Med       Date:  2022

Review 2.  Eggerthella lenta bacteremia successfully treated with ceftizoxime: case report and review of the literature.

Authors:  Shuming Jiang; Jianfei E; Dengchao Wang; Yanjiao Zou; Xiao Liu; Hualiang Xiao; Yuan Wen; Zongyao Chen
Journal:  Eur J Med Res       Date:  2021-09-20       Impact factor: 2.175

3.  Selective Isolation of Eggerthella lenta from Human Faeces and Characterisation of the Species Prophage Diversity.

Authors:  Colin Buttimer; Francesca Bottacini; Andrey N Shkoporov; Lorraine A Draper; Paul Ross; Colin Hill
Journal:  Microorganisms       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.